

24 July 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Result of General Meeting

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce that, further to the Company's announcement on 4 July 2025, at its General Meeting held today, all Resolutions were passed.

Accordingly, all proposals outlined in the Company's circular dated 7 July 2025 (the "Circular") will proceed and 266,246,757 Conditional Placing Shares (as defined in the announcement dated 4 July 2025) have been issued and application has been made for the admission of these shares to trading on AIM, which is expected to be effective from 8.00 am on or around 28 July 2025.

The full results of the voting will be published on the Company's website at <https://aptamergroup.com/investors/reports-and-presentations>.

Total Voting Rights

Immediately following Admission, the Company will have 2,660,978,377 Ordinary Shares of £0.001 each in issue. The Company does not hold any shares in treasury, and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

- Ends -

For further information, please contact:

Aptamer Group plc	+44 (0) 1904 217 404
Dr Arron Tolley	

SPARK Advisory Partners Limited - Nominated Adviser	+44 (0) 20 3368 3550
Andrew Emmott / Jade Bayat	

Turner Pope Investments (TPI) Limited - Broker	+44 (0) 20 3657 0050
James Pope / Andrew Thacker	

Northstar Communication Limited	+44 (0) 113 730 3896
Sarah Hollins	

About Aptamer Group plc

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the £210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. Aptamer has built a powerful Optimer® ecosystem with extensive expertise for future innovation

global pharmaceutical companies. It is also building valuable Optimer™ assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMPKQBQKBKDN0B